Creating a Pipeline of ActR2A/B Based Assets

The mAb based core of Sixpeaks’ proprietary activin receptor blockers provides an ideal basis for creating a platform of compounds concomitantly addressing multiple pharmacologies. The choice of modality is ultimately defined by technical feasibility and the underlying medical condition likely to benefit from pairing ActR2A/B blockade with additional disease modifying pharmacology.

There is a growing understanding of the biological role of activin 2A/B receptor blockade in improving metabolic fitness of skeletal muscle. Identification of (underserved) unmet medical needs in subsegments of sarcopenic obese patients provides guidance for our patient centric multipharmacology approach. A first example of this approach is provided by our GLP1 receptor agonist – ActR2A/B mAb conjugate destined to deliver adipose tissue specific weight loss with consequential relative expansion of skeletal muscle mass.